TIPE3上调P-gp表达降低乳腺癌细胞对阿霉素的敏感性
TIPE3 decreases breast cancer cell sensitivity to adriamycin by upregulating P-gp protein expression

DOI: 10.6040/j.issn.1671-7554.0.2017.210

Keywords: 乳腺癌,P-糖蛋白,肿瘤坏死因子-α诱导蛋白8样蛋白3,核因子-kappa B,阿霉素,
Nuclear factor-kappa B,Adriamycin,Tumor necrosis factor-α induced protein 8 like 3,Breast cancer,P-gp

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	刘晓, 邵方元, 陈宏远. 阿霉素抗肿瘤分子机制的研究进展[J].中国医药生物技术, 2012, 7(5): 373-375.
[2]	Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells[J]. Cancer Sci, 2007, 98(7): 1064-1069.
[3]	Xu JW, Li QQ, Tao LL, et al. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells[J]. Int J Oncol, 2011, 39(6): 1501-1509.
[4]	Amiri-Kordestani L, Basseville A, Kurdziel K, et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies[J]. Drug Resist Updat, 2012, 15(1-2): 50-61.
[5]	孙晓冉, 孙剑经, 张林西. 姜黄素逆转肿瘤多药耐药机制的研究进展[J]. 中国肿瘤, 2016, 25(4): 272-277. SUN Xiaoran, SUN Jianjing, ZHANG Linxi, et al. Research progress in curcumin reversal of multidrug resistance in tumor[J]. China Cancer, 2016, 25(4): 272-277.
[6]	韩嘉华,朱斯琦,谢燕. 黄酮类化合物抵抗P-糖蛋白介导肿瘤多药耐药特性机制研究进展[J]. 国际药学研究杂志, 2016, 43(5): 818-823. HAN Jihua, ZHU Siqi, XIE Yan. Mechanism of flavonoids against P-glycoprotein mediated tumor multidrug resistance: Research advances[J]. J Int Pharm Res, 2016, 43(5): 818-823.
[7]	马园园, 颜天华, 程涛, 等. P-糖蛋白在细胞膜的定位和功能研究进展[J]. 西北药学杂志, 2014, 29(4): 439-442. MA Yuanyuan, YAN Tianhua, CHENG Tao, et al. Research progress on the location and function of P-glycoprotein in cell membrane[J]. Northwest Pharmaceutical Journal, 2014, 29(4): 439-442.
[8]	Deng L, Lin-Lee YC, Claret FX, et al. 2-acetylaminofluorene up-regulates rat mdrlb expression through generating reactive oxygen species that activate NF-kappaB pathway[J]. J Biol Chem, 2001, 276(1): 413-420.
[9]	Kumar D, Gokhale P, Broustas C, et al. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB-435 cells[J]. Oncogene, 2004, 23(2): 612-616.
[10]	Sun H, Gong S, Carmody RJ, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis[J]. Cell, 2008, 133(3): 415-426.
[11]	Kumar D, Whiteside TL, Kasid U. Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein[J]. J Biol Chem, 2000, 275(4): 2973-2978.
[12]	Porturas TP, Sun H, Buchlis G, et al. Crucial roles of TNFAIP8 protein in regulating apoptosis and Listeria infection[J]. J Immunol, 2015, 194(12): 5743-5750.
[13]	Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway[J]. Cell, 2008, 135(7): 1311-1323.
[14]	Fayngerts SA, Wu J, Oxley CL, et al. TIPE3 is the transfer protein of lipid second messengers that promote cancer[J]. Cancer cell, 2014, 26(4): 465-478.
[15]	Kuo MT, Liu Z, Wei Y, et al. Inductio of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kB signaling[J]. Oncogene, 2002, 21(13): 1945-1954.
[16]	Morgan TM, Koreckij TD, Corey E, et al. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway[J]. Curr Cancer Drug Targets, 2009, 9(2): 237-249.
[17]	Zhang BG, Hu L, Zang MD, et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development[J]. Oncotarget, 2016, 7(9): 9788-9800.
[18]	Kaili Lian, Chao Ma, Chunyan Hao, et al. TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-κB signaling pathways[J]. Oncotarget, 2017, 23. doi: 10.18632/oncotarget.16522.
[19]	罗年安, 屈亚琦, 董瑞. 乳腺癌的治疗进展[J]. 现代生物医学进展, 2015, 15(1): 162-166. LUO Nianan, QU Yaqi, DONG Rui. The treatment progress of the breast cancer[J]. Progress in Modern Biomedicine, 2015, 15(1): 162-166.
[20]	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): 279-289.
[21]	Lei H, Wang X, Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations[J]. J Mol Graph Model, 2012, 38(9): 279-289.
[22]	Meszaros P, Klappe K, Hummel I, et al. Function of MRP1/ABCC1 is not dependent on cholesterol or cholesterol-stabilized lipid rafts[J]. Biochem J, 2011, 437(3): 483-491.
[23]	Gus-Brautbar Y, Johnson D, Zhang L, et al. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras[J]. Molecular cell, 2012, 45(5): 610-618.
[24]	Cui J, Hao C, Zhang W, et al. Identical expression profiling of human and murine TIPE3 protein reveals links to its functions[J]. J Histochem Cytochem, 2015, 63(3): 206-216.
[25]	Shaw JA, Stebbing J. Circulating free DNA in the management of breast cancer[J]. Ann Transl Med, 2014, 2(1): 3.
[26]	Ohta T. Breast cancer[J]. Nihon Rinsho, 2010, 68(Suppl 8): 438-443.
[27]	周志兵,魏文嵩,杨世昕,等. 紫杉醇联合表阿霉素、环磷酰胺治疗乳腺癌的近期疗效及安全性分析[J]. 医学理论与实践, 2017, 30(4): 550-551.
[28]	Osborn MT, Berry A, Ruberu MS, et al. Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways[J]. Oncogene, 1999, 18(42): 5756-5764;

Full-Text